Literature DB >> 30190804

A blood test to identify when melanoma metastasizes: a reality for melanoma management?

Eleftheria Hatzimichael1,1, Nel Syed2,2, Cristiana Lo Nigro3,3, Tim Crook4,4.   

Abstract

Entities:  

Keywords:  blood test; epigenetics; melanoma; metastasis; methylation

Year:  2014        PMID： 30190804      PMCID： PMC6094697          DOI： 10.2217/mmt.14.11

Source DB:  PubMed          Journal:  Melanoma Manag        ISSN： 2045-0885


× No keyword cloud information.
  8 in total

1.  Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy.

Authors:  Takuji Mori; Steven J O'Day; Naoyuki Umetani; Steve R Martinez; Minoru Kitago; Kazuo Koyanagi; Christine Kuo; Teh-Ling Takeshima; Robert Milford; He-Jing Wang; Vu D Vu; Sandy L Nguyen; Dave S B Hoon
Journal:  J Clin Oncol       Date:  2005-12-20       Impact factor: 44.544

2.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

3.  Follow-up with CA125 after primary therapy of advanced ovarian cancer has major implications for treatment outcome and trial performances and should not be routinely performed.

Authors:  G J S Rustin
Journal:  Ann Oncol       Date:  2011-12       Impact factor: 32.976

Review 4.  CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.

Authors:  Patrick A Ott; F Stephen Hodi; Caroline Robert
Journal:  Clin Cancer Res       Date:  2013-10-01       Impact factor: 12.531

Review 5.  The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be.

Authors:  Ryan J Sullivan; Patricia M Lorusso; Keith T Flaherty
Journal:  Clin Cancer Res       Date:  2013-10-01       Impact factor: 12.531

6.  AIM1 and LINE-1 epigenetic aberrations in tumor and serum relate to melanoma progression and disease outcome.

Authors:  Sojun Hoshimoto; Christine T Kuo; Kelly K Chong; Teh-Ling Takeshima; Yoshiki Takei; Michelle W Li; Sharon K Huang; Myung-Shin Sim; Donald L Morton; Dave S B Hoon
Journal:  J Invest Dermatol       Date:  2012-03-08       Impact factor: 8.551

7.  Methylated tissue factor pathway inhibitor 2 (TFPI2) DNA in serum is a biomarker of metastatic melanoma.

Authors:  Cristiana Lo Nigro; Hexiao Wang; Angela McHugh; Laura Lattanzio; Rubeta Matin; Catherine Harwood; Nelofer Syed; Eleftheria Hatzimichael; Evangelos Briasoulis; Marco Merlano; Alan Evans; Alastair Thompson; Irene Leigh; Colin Fleming; Gareth J Inman; Charlotte Proby; Tim Crook
Journal:  J Invest Dermatol       Date:  2013-02-14       Impact factor: 8.551

Review 8.  The context and potential of epigenetics in oncology.

Authors:  J Lopez; M Percharde; H M Coley; A Webb; T Crook
Journal:  Br J Cancer       Date:  2009-02-24       Impact factor: 7.640
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.